The analysis – from a dataset that spans more than half a million patients – reveals once again the lack of inclusivity in clinical research, which undermines the ability of clinical trials to generate results that reflect the real-world situation in US cancer treatment.
It was carried out by Phesi, a specialist in virtual clinical development and trial data analysis, which pointed out that the results show that a third of the US population is not being represented in clinical trials.
